12-046
Showing 1 - 25 of >10,000
Hunter Syndrome Trial in Canada, France (Idursulfase-IT, Elaprase)
Not yet recruiting
- Hunter Syndrome
-
Calgary, Alberta, Canada
- +3 more
Sep 4, 2023
Advanced NSCLC Trial in China (KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein
Enrolling by invitation
- Advanced Non-small Cell Lung Cancer
- KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
- Axitinib
-
Hefei, Anhui, China
- +5 more
Oct 26, 2022
Breast Cancer, Brain Metastases Trial in United States (Whole Brain Radiotherapy (WBRT), Sorafenib)
Completed
- Breast Cancer
- Brain Metastases
- Whole Brain Radiotherapy (WBRT)
- Sorafenib
-
Basking Ridge, New Jersey
- +5 more
Mar 4, 2022
Advanced / Metastatic Solid Tumors Trial (MAX-40279-01: 50mg/70mg)
Not yet recruiting
- Advanced / Metastatic Solid Tumors
- MAX-40279-01: 50mg/70mg
- (no location specified)
Jun 16, 2022
Surgical Procedure, Unspecified Trial in Tekirdag (Transversalis Fascial Plane Block, Quadratus Lumborum Plane Block)
Recruiting
- Surgical Procedure, Unspecified
- Transversalis Fascial Plane Block
- Quadratus Lumborum Plane Block
-
Tekirdağ, TurkeyTekirdag Namik Kemal University
Jan 9, 2023
Myocardial Infarction, Acute Trial in Poland (Ferinject, Sodium Chloride 0.9% Inj)
Recruiting
- Myocardial Infarction, Acute
- Ferinject
- Sodium Chloride 0.9% Inj
-
Wrocław, Dolnośląskie, Poland
- +14 more
Feb 24, 2023
HER2 Positive Solid Tumor Trial in Beijing (KN026 combined with KN046)
Recruiting
- HER2 Positive Solid Tumor
- KN026 combined with KN046
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Apr 6, 2022
STabilization of Atheroma By Lipid-reducing Effect of
Not yet recruiting
- Coronary Artery Disease
- +2 more
- SeQuent Please Neo
-
Ansan-si, Gyeonggi-do, Korea, Republic ofKorea University Ansan Hospital
Jun 24, 2022
Inguinal Hernia Trial in Erzurum (Bupivacaine Hydrochloride)
Recruiting
- Inguinal Hernia
- Bupivacaine Hydrochloride
-
Erzurum, TurkeyAtaturk University
Sep 29, 2021
HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)
Not yet recruiting
- HER2-positive Colorectal Cancer
- HER2-positive Biliary Tract Cancer
- KN026
- +2 more
-
Beijing, State*, ChinaPeking University cancer hospital & institution
Aug 2, 2023
Solid Tumor Trial in Tainan (GT90001+KN046, GT90001/KN046)
Recruiting
- Solid Tumor
-
Tainan, TaiwanChi-Mei Medical Center
Nov 25, 2021
Triple-negative Breast Cancer Trial in Beijing (KN046, Nab-paclitaxel)
Active, not recruiting
- Triple-negative Breast Cancer
- KN046
- Nab-paclitaxel
-
Beijing, Beijing, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medic
Nov 16, 2021
Cardiac Output, High, Heart Failure, Pulmonary Edema With Heart Failure Trial in Jakarta (Semifowler 30" Right Lateral Body
Recruiting
- Cardiac Output, High
- +4 more
- Semifowler 30" Right Lateral Body Position
-
Jakarta, West Jakarta, IndonesiaRyan Budiyanto
Sep 8, 2023
Artificial Intelligent System for Eye Emergency Triage and
Recruiting
- Emergencies
- Eye Diseases
- Artificial intelligent system for eye emergency triage and primary diagnosis
-
Guangzhou, Guangdong, ChinaZhongshan Ophthalmic Center, Sun Yat-sen Univerisity
Dec 25, 2022
Stress Disorders, Post-Traumatic, Brain Injuries, Transcranial Magnetic Stimulation Trial in Calgary (Repetitive Transcranial
Completed
- Stress Disorders, Post-Traumatic
- +5 more
- Repetitive Transcranial Magnetic Stimulation to Right Dorsolateral Prefrontal Cortex
- +2 more
-
Calgary, Alberta, CanadaFoothill Medical Centre
Nov 3, 2022
B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging
Active, not recruiting
- Chronic Lymphocytic Leukemia
-
Manhasset, New YorkFeinstein Institute for Medical Research
Jul 6, 2022
Neurocognition & Neuroimaging in Primary BT Patients
Recruiting
- Primary Brain Tumor
- +3 more
-
San Diego, CaliforniaMoores Cancer Center
Oct 7, 2022
Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV Trial in Guangzhou (Rifaximin 200 mg, Standard Treatment without
Recruiting
- Liver Failure, Acute on Chronic
- +5 more
- Rifaximin 200 mg
- Standard Treatment without Rifaximin
-
Guangzhou, Guangdong, ChinaThe Third Affiliated Hospital of Sun Yat-sen University
Mar 26, 2023